article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

Our pipeline, for example, includes a new class of recombinant antibodies. Right now, they are doing what is probably the most advanced work in the field of polyclonal recombinant antibody therapies. The science is brilliant.

Medicine 111
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

The luncheon presentations include: Matthias Hillenbrand, PhD, Head, Infectious Disease Research & Biosafety Officer, Memo Therapeutics, on: ‘Best in class antiviral antibodies from cognate recombinant antibody repertoires of human donors’. Crystal Richardson, Ph.D, Patrick Doonan, Ph.D.,